Active, not recruitingPhase 4NCT06121401

First Line Treatment With Olaparib in Combination With Bevacizumab in HRD Positive Patients

Studying Malignant epithelial tumor of ovary

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Mario Negri Institute for Pharmacological Research
Principal Investigator
Federica Tomao
Università degli Studi di Roma "La Sapienza", Viale del Policlinico 155, Roma
Intervention
Olaparib(drug)
Enrollment
190 target
Eligibility
18-75 years · FEMALE
Timeline
20232027

Study locations (2)

Collaborators

AstraZeneca

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06121401 on ClinicalTrials.gov

Other trials for Malignant epithelial tumor of ovary

Additional recruiting or active studies for the same condition.

See all trials for Malignant epithelial tumor of ovary

← Back to all trials